60,000 Shares in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Purchased by Sanctuary Advisors LLC

Sanctuary Advisors LLC purchased a new stake in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 60,000 shares of the company’s stock, valued at approximately $87,000. Sanctuary Advisors LLC owned about 0.13% of Verrica Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Simplify Asset Management Inc. bought a new position in shares of Verrica Pharmaceuticals during the second quarter worth approximately $2,041,000. XTX Topco Ltd acquired a new position in Verrica Pharmaceuticals in the 3rd quarter valued at $335,000. Verition Fund Management LLC bought a new position in Verrica Pharmaceuticals during the 3rd quarter worth $89,000. State Street Corp boosted its position in shares of Verrica Pharmaceuticals by 13.5% in the third quarter. State Street Corp now owns 512,821 shares of the company’s stock valued at $744,000 after acquiring an additional 61,041 shares during the period. Finally, Renaissance Technologies LLC acquired a new position in shares of Verrica Pharmaceuticals in the second quarter valued at about $332,000. 42.45% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have issued reports on VRCA. HC Wainwright downgraded shares of Verrica Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Wednesday, November 6th. Needham & Company LLC reiterated a “hold” rating on shares of Verrica Pharmaceuticals in a research note on Friday, December 20th. Brookline Capital Management restated a “hold” rating on shares of Verrica Pharmaceuticals in a research note on Wednesday, October 2nd. Royal Bank of Canada downgraded Verrica Pharmaceuticals from an “outperform” rating to a “sector perform” rating and cut their target price for the company from $11.00 to $2.00 in a research report on Tuesday, November 5th. Finally, TD Cowen decreased their price target on Verrica Pharmaceuticals from $15.00 to $10.00 and set a “buy” rating on the stock in a research report on Monday, October 21st. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $9.50.

Verrica Pharmaceuticals Trading Up 2.3 %

Shares of VRCA stock opened at $0.70 on Tuesday. Verrica Pharmaceuticals Inc. has a fifty-two week low of $0.61 and a fifty-two week high of $11.41. The stock’s fifty day moving average price is $1.03 and its two-hundred day moving average price is $3.24. The company has a debt-to-equity ratio of 29.58, a quick ratio of 1.22 and a current ratio of 1.34. The company has a market cap of $31.92 million, a PE ratio of -0.38 and a beta of 1.40.

Verrica Pharmaceuticals (NASDAQ:VRCA) last released its quarterly earnings data on Monday, November 4th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.12). The business had revenue of ($1.78) million during the quarter, compared to analyst estimates of $7.53 million. Verrica Pharmaceuticals had a negative net margin of 625.06% and a negative return on equity of 591.84%. Equities analysts predict that Verrica Pharmaceuticals Inc. will post -1.42 EPS for the current fiscal year.

Verrica Pharmaceuticals Profile

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.